U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07936201) titled 'Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia' on Nov. 09.
Brief Summary: This study is for participants who have been diagnosed with myelofibrosis with cytopenia. Luspatercept and Pacritinib are experimental drug combination that works by blocking certain enzymes to calm an overactive inmmune system to reduce inflammation which would allow red blood cells to mature. The purpose of this study is to find out if the combination of Luspatercept and Pacritinib can help improve hemobglobin or transfusion dependents in participants with myelofibrosis with cytopenias.
Study Start Date: Dec...